Teva bows out of voting on Mylan's proposed deal for Perrigo

Friday, Mylan's ($MYL) shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo ($PRGO). But Teva ($TEVA) won't be among them, despite the fact that it built up a 4.61% Mylan stake when it was trying to buy the company earlier this year. It'll refrain from attending the meeting or voting in it, the company said Tuesday, and it's still reviewing its options on what to do with its shares. 6-K | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.